p27(kip1) acts as a downstream effector of and is coexpressed with the β(1C) integrin in prostatic adenocarcinoma

Journal of Clinical Investigation

Volumn 103, Issue 3, 1999, Pages 321-329

  Fornaro, Mara ^a   Tallini, Giovanni ^a   Zheng, Duo Qi ^a   Flanagan, W Michael ^b   Manzotti, Michela ^a,c   Languino, Lucia R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; PROTEIN P27;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CHO CELL; DNA FLANKING REGION; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION; HYPOTHESIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RABBIT; TUMOR GROWTH;

EID: 0032930938     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI4585     Document Type: Article

References (44)

1. Hynes, R.O. 1992. Integrins: versatility, modulation and signaling in cell adhesion. Cell. 69: 11-25.
2. Ruoslahti, E., and Reed, J.C. 1994. Anchorage dependence, integrins and apoptosis. Cell. 77:477-478.
3. Schwartz, M.A., Schaller, M.D. and Ginsberg, M.H. 1995. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol. 11:549-599.
4. Howe, A., Aplin, A.E., Alahari, S.K., and Juliano, R.L. 1998. Integrin signaling and cell growth control. Curr. Opin. Cell Biol. 10:220-231.
5. Schlaepfer, D.D., and Hunter, T. 1998. Inregrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol. 8:151-157.
6. 1 subunit with a variant cytoplasmic domain. J. Biol. Chem. 267:7116-7120.
7. 1C inhibits prostate epithelial cell proliferation. Am. J. Pathol. 153:1079-1087.
8. 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. Am. J. Pathol. 149:765-773.
9. 1C cytoplasmic domain regulates cell proliferation. J. Biol. Chem. 270:24666-24669.
10. 1C. Science. 269:1570-1572.
11. Hunter, T., and Pines, J. 1994. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79:573-582.
12. Sherr, C.J., and Roberts, J.M. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149-1163.
13. K1pl is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58:542-548.
14. Yang, R.M., et al. 1998. Low P27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159:941-945.
15. K1pl protein: Prognostic implications in primary breast cancer. Nat. Med. 3:227-230.
16. K1pl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222-226.
17. Loda, M., et al. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:231-234.
18. Bottazzi, M.E., and Assoian, R.K. 1997. The extracellular matrix and mitogenic growth factors control G1 phase cyclins and cyclin-dependent kinase inhibitors. Trends Cell Biol. 7:348-352.
19. Guadagno, T.M., Ohtsubo, M., Roberts, J.M., and Assoian, R.K. 1993. A link between cyclin A expression and adhesion-dependent cell cycle progression. Science. 262:1572-1575.
20. Fang, F., Orend, G., Watanabe, N., Hunter, T., and Ruoslahti, E. 1996. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 271:499-502.
21. Zhu, X., Ohtsubo, M., Bohmer, R.M., Roberts, J.M., and Assoian, R.K. 1996. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol. 133:391-403.
22. Day, M.L., et al. 1997. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. J. Biol. Chem. 272:8125-8128.
23. Schulze, A., et al. 1996. Anchorage-dependent transcription of the cyclin A gene. Mol. Cell. Biol. 16:4632-4638.
24. Koyama, H., Raines, E.W., Bornfeldt, K.E., Roberts, J.M., and Ross, R. 1996. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 87:1069-1078.
25. Engvall, E., and Ruoslahti, E. 1977. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int. J. Cancer. 20:1-5.
26. Danielpour, D., Kadomatsu, K., Anzano, M.A., Smith, J.M., and Sporn, M.B. 1994. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res. 54:3413-3421.
27. Shockett, P., Difilippantonio, M., Hellman, N., and Schatz, D.G. 1995. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc. Natl. Acad. Sci. USA. 92:6522-6526.
28. Languino, L.R., et al. 1993. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1 dependent pathway. Cell. 73:1423-1434.
29. Zhang, H., Kobayashi, R., Galaktionov, K., and Beach, D. 1995. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 phase kinase. Cell. 82:915-925.
30. Matsushime, H., et al. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066-2076.
31. k1pl. Mol. Cell. Biol. 17:3850-3857.
32. K1pl for restriction point control of the fibroblast cell cycle. Science. 272:877-880.
33. Chen, Q., Kinch, M.S., Lin, T.H., Burridge, K., and Juliano, R.L. 1994. Integrin-mediated cell adhesion activates mitogen-activated protein kinases. J. Biol. Chem. 269:26602-26605.
34. Keely, P., Parise, L., and Juliano, R. 1998. Integrins and GTPases in tumor cell growth, motility and invasion. Trends Cell Biol. 8:101-106.
35. 1 integrin functions alters the development of murine mammary glands. EMBO J. 17:2139-2147.
36. Albelda, S.M. 1993. Biology of disease: role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Invest. 68:4-17.
37. Carroll, J.M., Romero, R.M., and Watt, F.M. 1995. Suprabasal integrin expression in epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell. 83:957-968.
38. 4 integrin cytoplasmic domain. J. Biol. Chem. 270:22673-22676.
39. uafl pathway in response to disruption of cell-matrix interactions. J. Biol. Chem. 272:29091-29098.
40. Schlaepfer, D.D., Jones, K.C., and Hunter, T. 1998. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol. Cell. Biol. 18:2571-2585.
41. Fornaro, M., and Langumo, L.R. 1997. Alternatively spliced variants: a new view of the integrin cytoplasmic domain. Matrix Biol. 16:185-193.
42. Wei, J., Shaw, L., and Mercurio, A.M. 1998. Regulation of mitogen-activated protein kinase activation by the cytoplasmic domain of the α6 integrin subunit. J. Biol. Chem. 273:5903-5907.
43. 1D integrin inhibits cell cycle progression in normal myoblasts and fibroblasts. J. Biol. Chem. 273:15234-15240.
44. 1 exon D define distinct roles for integrin splice variants in heart function and embryonic development. Genes Dev. 12:1202-1216.